Dimensional Fund Advisors LP Decreases Stock Position in Vera Therapeutics, Inc. $VERA

Key Points

• Dimensional Fund Advisors reduced its Vera Therapeutics position by 20.8% in the first quarter, selling 73,121 shares and retaining 278,765 shares valued at $11.2 million. Institutional investors collectively own 99.21% of the company.
• Analyst sentiment remains positive, with 11 Buy ratings, one Hold, and one Sell; Vera has a consensus “Moderate Buy” rating and an average price target of $84.58.
• CEO Marshall Fordyce sold 46,250 shares for approximately $2.0 million under a Rule 10b5-1 plan. Vera shares opened at $32.89, while the company’s latest quarterly loss of $1.69 per share missed expectations of a $1.33 loss.

Dimensional Fund Advisors LP decreased its position in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 20.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 278,765 shares of the company's stock after selling 73,121 shares during the quarter. Dimensional Fund Advisors LP owned 0.39% of Vera Therapeutics worth $11,215,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Vera Therapeutics by 7.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,905 shares of the company's stock worth $753,000 after purchasing an additional 2,210 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Vera Therapeutics by 22.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 98,013 shares of the company's stock worth $2,354,000 after acquiring an additional 17,907 shares in the last quarter. Jane Street Group LLC grew its holdings in Vera Therapeutics by 297.1% during the 1st quarter. Jane Street Group LLC now owns 41,578 shares of the company's stock worth $999,000 after acquiring an additional 62,678 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Vera Therapeutics by 550.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 310,547 shares of the company's stock worth $7,316,000 after purchasing an additional 262,805 shares during the last quarter. Finally, Legal & General Group Plc increased its position in shares of Vera Therapeutics by 1.7% in the 2nd quarter. Legal & General Group Plc now owns 50,418 shares of the company's stock worth $1,188,000 after purchasing an additional 825 shares during the last quarter. Hedge funds and other institutional investors own 99.21% of the company's stock.

Wall Street Analyst Weigh In

VERA has been the subject of a number of research reports. Guggenheim lifted their price target on Vera Therapeutics from $56.00 to $76.00 and gave the stock a "buy" rating in a research note on Wednesday, July 8th. Weiss Ratings restated a "sell (d-)" rating on shares of Vera Therapeutics in a research note on Friday, July 17th. HC Wainwright increased their target price on Vera Therapeutics from $110.00 to $125.00 and gave the stock a "buy" rating in a report on Wednesday, July 8th. Needham & Company LLC set a $125.00 target price on Vera Therapeutics in a report on Wednesday, July 8th. Finally, Wedbush boosted their price target on Vera Therapeutics from $35.00 to $43.00 and gave the company a "neutral" rating in a report on Wednesday, July 8th. Eleven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $84.58.

Insider Transactions at Vera Therapeutics

In other Vera Therapeutics news, CEO Marshall Fordyce sold 46,250 shares of Vera Therapeutics stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $42.30, for a total transaction of $1,956,375.00. Following the sale, the chief executive officer owned 151,994 shares of the company's stock, valued at $6,429,346.20. The trade was a 23.33% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 83,250 shares of company stock valued at $3,337,770. Corporate insiders own 15.90% of the company's stock.

Vera Therapeutics Stock Performance

Shares of NASDAQ VERA opened at $32.89 on Monday. Vera Therapeutics, Inc. has a 12-month low of $19.25 and a 12-month high of $56.05. The company has a market cap of $2.36 billion, a price-to-earnings ratio of -5.94 and a beta of 0.92. The company has a current ratio of 13.64, a quick ratio of 13.64 and a debt-to-equity ratio of 0.15. The stock's 50 day simple moving average is $36.58 and its 200 day simple moving average is $39.02.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last issued its earnings results on Thursday, May 7th. The company reported ($1.69) earnings per share for the quarter, missing the consensus estimate of ($1.33) by ($0.36). During the same period in the previous year, the business earned ($0.81) earnings per share. Equities research analysts expect that Vera Therapeutics, Inc. will post -6.37 EPS for the current year.

Vera Therapeutics Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body's own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.

Want to see what other hedge funds are holding VERA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source